Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05774652
Other study ID # LiPO-Teen
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2023
Est. completion date April 1, 2026

Study information

Verified date January 2023
Source Odense University Hospital
Contact Christina A. Vinter, M.D. Ph.D.
Phone +45 21782118
Email Christina.vinter@rsyd.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a follow-up of a Randomized Controlled Trial (RCT) performed in 2007-10 - the "Lifestyle in Pregnancy" LiP study. The LiP study included 360 pregnant women with BMI ≥30 kg/m2 from Odense University Hospital and Aarhus University Hospital. The women were randomized to intervention with low-calorie diet and physical activity from gestational age 10-14 in pregnancy and until delivery - or to a standard care control group. The objective of the LiPO-Teen project is to perform a clinical follow-up study of the eligible 301 mothers who completed the trial until delivery with a liveborn child, and their 14 year-old offspring. The overall ambition is to understand whether lifestyle intervention in pregnancy prevents obesity and its complications across generations, with a specific focus on modifiable factors.


Description:

LiPO Teen (the Lifestyle in Pregnancy and Offspring Teenagers): Identification of modifiable risk factors for childhood obesity - a follow-up of a randomized controlled trial. The objective of the LiPO-Teen project is to perform a clinical follow-up study of the eligible 301 mothers who completed the trial until delivery with a liveborn child, and their 14 year-old offspring. In the original trial women were randomized 1:1 to intervention or control. The participants (both mother and child in pair) who completed the initial LiP study will be invited to a 2-hour examination now 14 years after the intervention during pregnancy to evaluate the effect of the intervention on both mother and child long term.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 301
Est. completion date April 1, 2026
Est. primary completion date April 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 65 Years
Eligibility Inclusion Criteria: - Mothers in the initial LiP study selected at the baseline study in 2007-2010 - Teenagers of mothers in the initial LiP study Exclusion Criteria: • None

Study Design


Intervention

Behavioral:
Lifestyle intervention Dietary advise and/or advise on physical activity
Lifestyle intervention Dietary advise and/or advise on physical activity

Locations

Country Name City State
Denmark Steno Diabetes Center Odense Odense

Sponsors (6)

Lead Sponsor Collaborator
Odense University Hospital Aarhus University Hospital, Statens Serum Institut, Steno Diabetes Center Odense, University of Aarhus, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fat mass index , measured by DEXA scan. Body composition Assessed by Dual-Energy X-ray Absorptiometry (DEXA). Hologic Horizon, serie number: 301872M. Fat mass, lean mass and bone density will be calculated.
Fat mass index in both mothers and offspring (Fat mass index (FMI) defined as: FM (kg) / height (m)2).
2 years data collection
Secondary Glycemic variability Continuous glucose monitoring (CGM, DEXCOM G6Pro): 10 days recording of fasting glucose and postprandial glucose values. Glucose variability will be assessed using a device, which performs repeated glucose measurements in the skin providing insights into glucose fluctuations throughout the day and night. 2 years data collection
Secondary Mental health Assessed by questionnaires, validated to mother and child respectively 2 years data collection
Secondary Diet composition Assessed by FFQ (food frequency questionnaire), validated to mother and child respectively 2 years data collection
Secondary Physical activity (PA) Pattern and level of PA will be measured 7 days (24/7) monitored by activity tracker on the wrist (Actigraph GT3X+). 2 years data collection
Secondary Puberty stage According to the classifications of Marshall and Tanner 2 years data collection
Secondary Blood pressure Standardized sitting measurement, average of 3 measures. Both systolic and diastolic blood pressure will be measured. 2 years data collection
Secondary Epigenetic examinations Blood samples:
The epigenetic profile of DNA samples extracted from whole blood will be characterized by Genome-wide DNA methylation using Infinium MethylationEPIC v2.0 Kit. Principle component and hierarchical clustering analyses will be used to identify associations between methylation patterns and a range of clinical characteristics, biomarkers as well as gene expression levels (RNAseq).
2 years data collection
Secondary Metabolic and inflammatory markers Blood samples: Glucose 2 years data collection
Secondary HbA1c Blood samples: HbA1c 2 years data collection
Secondary Metabolic markers Blood samples: Lipids (total cholesterol, HDL, LDL, triglyceride) 2 years data collection
Secondary Electrolytes Blood sample: Electrolytes 2 years data collection
Secondary Insulin Blood sample: Insulin 2 years data collection
Secondary Vitamin D Blood sample: Vitamin D 2 years data collection
Secondary Selenium Blood sample: Selenium 2 years data collection
Secondary Zinc. Blood sample: Zinc 2 years data collection
Secondary C-peptide Blood sample: C-peptid 2 years data collection
Secondary Leptin Blood sample: Leptin 2 years data collection
Secondary Adiponectin Blood sample: Adiponectin. 2 years data collection
Secondary HsCRP. Blood sample: HsCRP. 2 years data collection
Secondary IL6 Blood sample: IL6 2 years data collection
Secondary Ferritin Blood sample: Ferritin 2 years data collection
Secondary Leukocytes Blood sample: Leukocytes 2 years data collection
Secondary Kidney function (e-GFR) Blood sample: Kidney function (e-GFR) 2 years data collection
Secondary Liver enzymes Blood sample: Liver enzymes 2 years data collection
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2